ClinicalTrials.gg
CompletedNCT05097716Updated Oct 6, 2023Results posted

Study to Evaluate the Effect of Multiple-Dose Ritlecitinib on the Pharmacokinetics (PK) of Tolbutamide

A Phase 1 interventional study of Ritlecitinib and Tolbutamide in Healthy Volunteers, sponsored by Pfizer. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-10-06.

Sponsored by Pfizer · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This is a Phase 1, 2-period, multiple-dose, open-label, single fixed sequence study of the effect of ritlecitinib on tolbutamide pharmacokinetics in healthy participants.

Read the detailed description

A total of approximately 12 healthy male and/or female participants will be enrolled in the study to obtain at least 10 evaluable participants who complete the study. This is an open-label study not requiring an assessment of efficacy or pharmacodynamics markers, but it will include pharmacokinetic estimation drug-drug interactions.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • pharmacokinetics (PK)
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and/or female participants who are healthy as determined by medical evaluation including medical history, full physical examination (including BP and pulse rate measurements), clinical laboratory tests, and 12-lead .
  • of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lb).

Exclusion criteria

Exclusion Criteria:

  • Past/present hematological, renal, endocrine, pulmonary, GI, CV, hepatic, psychiatric, neurological, dermatological or allergic disease (including drug allergies).
  • Any condition possibly affecting drug absorption (eg, gastrectomy, cholecystectomy).
  • Infection with or C viruses.
  • Participants with any of the following acute or chronic infections or infection history: any infection requiring treatment within 2 weeks prior to the start of study participation; any infection requiring hospitalization or parenteral antimicrobial therapy within 60 days of the first dose of product; any infection judged to be an opportunistic infection or clinically significant within the past 6 months of the first dose of investigational product; known active or history of recurrent bacterial, viral, fungal, mycobacterial or other infections; history of recurrent localized dermatomal herpes zoster, or history of disseminated (single episode) herpes simplex or disseminated herpes zoster.
  • History of any lymphoproliferative disorder such as EBV related lymphoproliferative disorder, history of lymphoma, history of leukemia, or signs or symptoms suggestive of current lymphatic or lymphoid disease.
  • Known presence or a history of other than a successfully treated or excised non- basal cell or squamous cell cancer of the skin or cervical carcinoma in situ.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Ritlecitinib and tolbutamide

    In Period 1, participants will be dosed with a single administration of tolbutamide 500 mg tablet on Day 1. Period 1 will be immediately followed by Period 2 with no washout. In Period 2, participants will be dosed with oral 200 mg ritlecitinib QD for 10 days followed by administration of a single dose of 500 mg tolbutamide oral tablet within approximately 5 minutes after administration of a 200 mg dose of ritlecitinib on the morning of Day 10.

    Drug: Ritlecitinib · Drug: Tolbutamide

Interventions

  • Ritlecitinib 200 mg provided as four 50 mg oral capsules

    Also known as: PF-06651600

  • Tolbutamide 500 mg provided as one 500 mg oral tablet

06

What researchers measure

Primary outcomes

  1. Maximum Plasma Concentration (Cmax) of Tolbutamide Administered With and Without Ritlecitinib

    Cmax was defined as maximum observed plasma concentration. The determination method of Cmax was observing directly from data.

    Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, and 36 hours post-dose of tolbutamide in Period 1 (Days 1 and 2) and Period 2 (Days 10 and 11)

  2. Area Under the Plasma Concentration Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf) of Tolbutamide Administered With and Without Ritlecitinib

    AUCinf was defined as area under the plasma concentration time profile from time 0 extrapolated to infinite time.

    Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, and 36 hours post-dose in Period 1 (Days 1 and 2) and Period 2 (Days 10 and 11)

Secondary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs) - All Causalities and Treatment Related

    An adverse event (AE) was any untoward medical occurrence in a clinical investigation where participants were administered a product; the event needed not necessarily have a causal relationship with the treatment or usage. TEAEs were events between first dose of study drug and up to discharge from study that were absent before treatment or that worsened relative to pretreatment state. A treatment-related AE was any untoward medical occurrence attributed to the study drug in a participant who received study drug.

    Time frame: From screening up to a follow-up phone call between 28 and 35 calendar days after the last administration of the investigational product and early termination (if applicable)

07

Results

Posted Oct 6, 2023

Participant flow

Period 1
Participant flow — Period 1
MilestonePeriod 1: Tolbutamide and Period 2: Ritlecitinib + Tolbutamide
Started12
Completed10
Not completed2
Withdrew: Adverse event1
Withdrew: Close contact with highly-transmissible infection1
Period 2
Participant flow — Period 2
MilestonePeriod 1: Tolbutamide and Period 2: Ritlecitinib + Tolbutamide
Started10
Completed10
Not completed0

Outcome measures

PrimaryMaximum Plasma Concentration (Cmax) of Tolbutamide Administered With and Without Ritlecitinib

Cmax was defined as maximum observed plasma concentration. The determination method of Cmax was observing directly from data.

Time frame:
Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, and 36 hours post-dose of tolbutamide in Period 1 (Days 1 and 2) and Period 2 (Days 10 and 11)
Reported as:
Geometric mean · ng/mL (nanogram/milliliter)
Maximum Plasma Concentration (Cmax) of Tolbutamide Administered With and Without Ritlecitinib
ng/mL (nanogram/milliliter)Period 1: TolbutamidePeriod 2: Ritlecitinib + Tolbutamide
Maximum Plasma Concentration (Cmax) of Tolbutamide Administered With and Without Ritlecitinib44240 ± 1545740 ± 17
Statistical analysis
  • Period 1: Tolbutamide vs Period 2: Ritlecitinib + Tolbutamide · Ratio of adjusted geometric means: 103.01 · 90% CI 96.66 to 109.77The comparison was Test vs. Reference (Ritlecitinib + Tolbutamide vs. Tolbutamide).
PrimaryArea Under the Plasma Concentration Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf) of Tolbutamide Administered With and Without Ritlecitinib

AUCinf was defined as area under the plasma concentration time profile from time 0 extrapolated to infinite time.

Time frame:
Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, and 36 hours post-dose in Period 1 (Days 1 and 2) and Period 2 (Days 10 and 11)
Reported as:
Geometric mean · ng*hr/mL
Area Under the Plasma Concentration Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf) of Tolbutamide Administered With and Without Ritlecitinib
ng*hr/mLPeriod 1: TolbutamidePeriod 2: Ritlecitinib + Tolbutamide
Area Under the Plasma Concentration Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf) of Tolbutamide Administered With and Without Ritlecitinib608600 ± 20586500 ± 30
Statistical analysis
  • Period 1: Tolbutamide vs Period 2: Ritlecitinib + Tolbutamide · Ratio of adjusted geometric means: 99.05 · 90% CI 92.01 to 106.62The comparison was Test vs. Reference (Ritlecitinib + Tolbutamide vs. Tolbutamide).
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs) - All Causalities and Treatment Related

An adverse event (AE) was any untoward medical occurrence in a clinical investigation where participants were administered a product; the event needed not necessarily have a causal relationship with the treatment or usage. TEAEs were events between first dose of study drug and up to discharge from study that were absent before treatment or that worsened relative to pretreatment state. A treatment-related AE was any untoward medical occurrence attributed to the study drug in a participant who received study drug.

Time frame:
From screening up to a follow-up phone call between 28 and 35 calendar days after the last administration of the investigational product and early termination (if applicable)
Reported as:
Number · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) - All Causalities and Treatment Related
ParticipantsPeriod 1: TolbutamidePeriod 2: RitlecitinibPeriod 2: Ritlecitinib + Tolbutamide
All-Causality122
Treatment-Related001

Adverse events

Collected over From screening up to a follow-up phone call between 28 and 35 calendar days after the last administration of the investigational product and early termination (if applicable). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Period 1: Tolbutamide0/12 (0%)0/12 (0%)1/12 (8.3%)
Period 2: Ritlecitinib0/10 (0%)0/10 (0%)2/10 (20%)
Period 2: Ritlecitinib + Tolbutamide0/10 (0%)0/10 (0%)2/10 (20%)
Most frequent other events
Most frequent other events
EventPeriod 1: TolbutamidePeriod 2: RitlecitinibPeriod 2: Ritlecitinib + Tolbutamide
PainGeneral disorders0/121/100/10
COVID-19Infections and infestations1/120/101/10
HypoglycaemiaMetabolism and nutrition disorders0/120/101/10
Nail disorderSkin and subcutaneous tissue disorders0/121/100/10

Baseline characteristics

Baseline analysis population included all participants assigned to the study intervention.

Age, Continuous
Age, Continuous(Years)MaleFemaleTotal
Mean37.4 ± 12.5748.7 ± 11.1540.3 ± 12.78
Age, Continuous
Age, Continuous(Years)MaleFemaleTotal
Median36.0 (23.0 to 57.0)53.0 (36.0 to 57.0)37.0 (23.0 to 57.0)
Age, Customized
Age, Customized(Participants)MaleFemaleTotal
<18000
18-44617
45-64325
>=65000
Sex: Female, Male
Sex: Female, Male(Participants)MaleFemaleTotal
Female033
Male909
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)MaleFemaleTotal
Hispanic or Latino112
Not Hispanic or Latino8210
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)MaleFemaleTotal
White527
Black or African American404
Asian011
08

Study locations

1 site
  • New Haven Clinical Research Unit
    New Haven, Connecticut 06511, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2021 to primary completion in Jan 2022, 2 months.

Results were first posted in Oct 2023, 1 year 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 14, 2021
First posted
Oct 28, 2021
StartActual
Nov 2, 2021
Primary completionActual
Jan 10, 2022
CompletionActual
Jan 10, 2022
Results first posted
Oct 6, 2023
Last update
Oct 6, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05097716
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Oct 28, 2021
Start date
Nov 2, 2021
Primary completion
Jan 10, 2022
Completion
Jan 10, 2022
Results posted
Oct 6, 2023
Last update
Oct 6, 2023

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: PF-06651600 · Tolbutamide

Start the discussion